These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 17947470)
1. Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Kumar SR; Quinn TP; Deutscher SL Clin Cancer Res; 2007 Oct; 13(20):6070-9. PubMed ID: 17947470 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764 [TBL] [Abstract][Full Text] [Related]
3. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. Kumar SR; Deutscher SL J Nucl Med; 2008 May; 49(5):796-803. PubMed ID: 18413389 [TBL] [Abstract][Full Text] [Related]
4. Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display. Larimer BM; Thomas WD; Smith GP; Deutscher SL Mol Imaging Biol; 2014 Aug; 16(4):449-58. PubMed ID: 24550054 [TBL] [Abstract][Full Text] [Related]
5. (64)Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen-Friedenreich carbohydrate antigen. Kumar SR; Gallazzi FA; Quinn TP; Deutscher SL J Nucl Med; 2011 Nov; 52(11):1819-26. PubMed ID: 21984800 [TBL] [Abstract][Full Text] [Related]
6. In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas. Deutscher SL; Figueroa SD; Kumar SR J Labelled Comp Radiopharm; 2009 Dec; 52(14):583-590. PubMed ID: 20976123 [TBL] [Abstract][Full Text] [Related]
7. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729 [TBL] [Abstract][Full Text] [Related]
8. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Deutscher SL; Figueroa SD; Kumar SR Nucl Med Biol; 2009 Feb; 36(2):137-46. PubMed ID: 19217525 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides. Guo H; Lu J; Hathaway H; Royce ME; Prossnitz ER; Miao Y Bioconjug Chem; 2011 Aug; 22(8):1682-9. PubMed ID: 21749045 [TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747 [TBL] [Abstract][Full Text] [Related]
11. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342 [TBL] [Abstract][Full Text] [Related]
12. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules. Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380 [TBL] [Abstract][Full Text] [Related]
13. Preparation and Okarvi SM; Aljammaz I Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105 [TBL] [Abstract][Full Text] [Related]
14. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers. Giblin MF; Gali H; Sieckman GL; Owen NK; Hoffman TJ; Volkert WA; Forte LR Breast Cancer Res Treat; 2006 Jul; 98(1):7-15. PubMed ID: 16724166 [TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors. Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265 [TBL] [Abstract][Full Text] [Related]
17. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. Hoffman TJ; Gali H; Smith CJ; Sieckman GL; Hayes DL; Owen NK; Volkert WA J Nucl Med; 2003 May; 44(5):823-31. PubMed ID: 12732685 [TBL] [Abstract][Full Text] [Related]
18. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729 [TBL] [Abstract][Full Text] [Related]
19. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621 [TBL] [Abstract][Full Text] [Related]